Supplementation with CoQ10 lowers age-related (ar) NOX levels in healthy subjects.
Our work has identified an aging-related ECTO-NOX activity (arNOX), a hydroquinone oxidase which is cell surface located and generates superoxide. This activity increases with increasing age beginning >30 y. Because of its cell surface location and ability to generate superoxide, the arNOX proteins may serve to propagate an aging cascade both to adjacent cells and to oxidize circulating lipoproteins as significant factors determining atherogenic risk. The generation of superoxide by arNOX proteins is inhibited by Coenzyme Q10 as one basis for an anti-aging benefit of CoQ10 supplementation in human subjects. In a preliminary pilot study, 25 female subjects between 45 and 55 y of age were recruited at Stanford University from the Palo Alto, CA area. Informed consent was obtained. Ten of the subjects received Coenzyme Q10 supplementation of 180 (3 x 60 mg) per day for 28 days. Serum, saliva and perspiration levels of arNOX were determined at 7, 14 and 28 days of CoQ10 supplementation and compared to the initial baseline value. Activity correlated with subject age up to a maximum between age 50 and 55 years of age for saliva and perspiration as well and then declined. With all three sources, the arNOX activity extrapolated to zero at about age 30. Response to Coenzyme Q10 also increased with age being least between ages 45 and 50 and greatest between ages 60 and 65. With all three biofluids, arNOX activity was reduced between 25 and 30% by a 3 x 60 mg daily dose Coenzyme Q10 supplementation. Inhibition was the result of Coenzyme Q10 presence.
Morré
Dorothy M
DM
Department of Foods and Nutrition, Purdue University, West Lafayette, IN, USA. morredm@purdue.edu
Morré
D James
DJ
Rehmus
Wingfield
W
Kern
Dale
D
D000328:Adult; D000368:Aged; D000375:Aging; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009247:NADH, NADPH Oxidoreductases / Q000187:drug effects / Q000378:metabolism*; D010865:Pilot Projects; D012463:Saliva / Q000187:drug effects / Q000201:enzymology; D013542:Sweat / Q000187:drug effects / Q000201:enzymology; D014451:Ubiquinone / Q000008:administration & dosage / Q000031:analogs & derivatives*
D014451:Ubiquinone; D009247:NADH, NADPH Oxidoreductases; C431909:tumor-associated NADH oxidase; C024989:coenzyme Q10